Valion Bio (VBIO) Cash from Operations (2021 - 2025)
Valion Bio (VBIO) posted quarterly Cash from Operations of 2300000.0 for Q4 2025, down 237.24% year-over-year from 1675854.7 in Q4 2024, and down 15.0% quarter-over-quarter from 2000000.0 in Q3 2025.
Valion Bio (VBIO) Cash from Operations (2021 - 2025) Analysis & Trends
Valion Bio's Cash from Operations history runs 5 years deep, the most recent figure standing at 2300000.0 for Q4 2025.
- In Q4 2025, Cash from Operations fell 237.24% year-over-year to 2300000.0; the TTM figure through Dec 2025 stood at 7000000.0 (down 37.74% YoY), while the FY2025 annual figure was 7000000.0, down 37.74% from the prior year.
- Cash from Operations for Q4 2025 stood at 2300000.0, down from 2000000.0 in the prior quarter.
- The five-year high for Cash from Operations was 543000.0 in Q2 2021, with the low at 2800000.0 in Q3 2022.
- The 5-year median for Cash from Operations is 1800000.0 (2023), against an average of 1756200.0.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 62.34% in 2024, then plunged 237.24% in 2025.
- Valion Bio's Cash from Operations stood at 2760000.0 in 2021, then rose by 19.6% to 2219000.0 in 2022, then advanced by 18.39% to 1811000.0 in 2023, then surged by 62.34% to 682000.0 in 2024, then slumped by 237.24% to 2300000.0 in 2025.
- Business Quant data shows VBIO's Cash from Operations at 2300000.0 in Q4 2025, 2000000.0 in Q3 2025, and 1800000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 728.46 Mn |
| 10 | Valion Bio | 410,331.63 | -1.79 Mn | -45,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.30 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Mar 31, 2025 | -900,000.00 |
| Mar 31, 2025 | -900,000.00 |
| Dec 31, 2024 | -682,000.00 |
| Dec 31, 2024 | -682,000.00 |
| Sep 30, 2024 | -1.45 Mn |
| Sep 30, 2024 | -1.45 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Sep 30, 2023 | -1.80 Mn |
| Sep 30, 2023 | -1.80 Mn |